Edit
Hyperion Therapeutics
http://hyperiontx.com/Last activity: 06.07.2021
Active - Reference to Viela Bio
Specialty therapeutics company focused on gastrointestinal and hepatology diseases and programs
Total raised: $60M
Investors 3
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Sofinnova ... | sofinnova.... |
| - | Bay City C... | baycitycap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.07.2009 | - | $60M | - |
Mentions in press and media 14
| Date | Title | Description |
| 30.03.2015 | Hyperion Therapeutics to be Acquired by Horizon Pharma plc for $46.00 per Share or $1.1 Billion in Cash | Brisbane, CA and Dublin, Ireland — Horizon Pharma plc (NASDAQ: HZNP) and Hyperion Therapeutics, Inc. (NASDAQ: HPTX) today announced they have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and ... |
| 03.06.2014 | Hyperion Therapeutics Announces Health Canada Accepts RAVICTI(R) New Drug Submission With Priority Review | Brisbane, CA — Hyperion Therapeutics, Inc. HPTX -2.11% today announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cyc... |
| 08.10.2013 | Bay City Capital Names Ashley Ledbetter Dombkowski, PhD, Managing Director | San Francisco, CA — Bay City Capital, a leading venture capital firm focused on early-stage to growth equity investments in the life sciences, today announced Ashley Dombkowski, Ph.D. joined as Managing Director. “Drug discovery and develo... |
| 13.05.2013 | Bay City Capital Expands Team with the Addition of David Beier, JD | San Francisco, CA — Bay City Capital, a leading venture capital firm focused on early-stage to growth equity investments in the life sciences, today announced the addition of David Beier, JD as Managing Director. David served as a senior of... |
| 01.02.2013 | Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders | Anticipated market launch by end of April 2013 Patent allowance extends coverage to 2032 February 1, 2013 South San Francisco, CA — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the U.S. Food and Drug Administration (FDA... |
| 26.07.2012 | Hyperion Therapeutics Announces Pricing of Initial Public Offering | July 26, 2012 South San Francisco, CA — Hyperion Therapeutics, Inc. (NASDAQ:HPTX) announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at $10.00 per share, before underwriting discounts and com... |
| 03.11.2010 | Hyperion Hits Goal in Trial for Rare-Disease Drug, Prepping FDA Application | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Hyperion Therapeutics raised $60 million in venture capital a year ago, and it should be in a position fairly soon to generate some return on that investment. The South San Fr... |
| 18.03.2010 | Horizon Therapeutics raises $8M for pain relief drugs | To make matters more confusing, Horizon filed another fundraising document with the SEC, saying that it had raised $17 million from the sale of debt, options and other securities. However, that filing lists the date of first sale as Oct. 28... |
| 06.07.2009 | Hyperion raises $60M to battle urea cycle disorders | Hyperion Therapeutics, developer of treatments for urea cycle disorders and illnesses, has brought in $60 million in a third round of financing from Bay City Capital, Panorama Capital, Highland Capital Partners, New Enterprise Associates an... |
| 18.05.2009 | Hyperion brings in $13M for gastrointestinal relief | Hyperion Therapeutics, maker of pharmaceuticals to treat hepatology and gastrointenstinal conditions, has raised $13 million of an anticipated $15 million round of debt, according to VentureWire. Contributors have not been disclosed, but th... |
Show more